|
Frequencies of conventional prognostic factors and adjuvant treatments in the test set |
|||||
| Factor |
Division |
Whole set (313 patients) |
Subset (227 patients) |
||
| n |
Percentage |
n |
Percentage |
||
|
|
|||||
| Age |
≤40 |
34 |
10.9 |
25 |
11.0 |
| >40 |
279 |
89.1 |
202 |
89.0 |
|
| Menopausal status |
Pre |
104 |
33.2 |
76 |
33.5 |
| Post |
203 |
64.9 |
147 |
64.8 |
|
| Unknown |
6 |
1.9 |
4 |
1.8 |
|
| Tumor grade |
1 |
5 |
1.6 |
4 |
1.8 |
| 2 |
101 |
32.3 |
71 |
31.3 |
|
| 3 |
191 |
61.0 |
144 |
63.4 |
|
| Unknown |
16 |
5.1 |
8 |
3.5 |
|
| Tumor size, cm |
0–2 |
100 |
31.9 |
71 |
31.3 |
| > 2–5 |
173 |
55.3 |
131 |
57.7 |
|
| > 5 |
35 |
11.2 |
22 |
9.7 |
|
| Unknown |
5 |
1.6 |
3 |
1.3 |
|
| Pathological ER status |
Negative |
72 |
23.0 |
54 |
23.8 |
| Positive |
234 |
74.8 |
169 |
74.4 |
|
| Unknown |
7 |
2.2 |
4 |
1.8 |
|
| Lymphovascular invasion |
Negative |
49 |
15.7 |
33 |
14.5 |
| Positive |
244 |
78.0 |
184 |
81.1 |
|
| Unknown |
20 |
6.4 |
10 |
4.4 |
|
| Percentage of positive nodes |
0–50 |
121 |
38.7 |
89 |
39.2 |
| >50–99.9 |
142 |
45.4 |
95 |
41.9 |
|
| 100 |
50 |
16.0 |
43 |
18.9 |
|
| Number of positive nodes |
4–9 |
235 |
75.1 |
175 |
77.1 |
| ≥10 |
78 |
24.9 |
52 |
22.9 |
|
| Histology |
Ductal |
279 |
89.1 |
210 |
92.5 |
| Lobular |
34 |
10.9 |
17 |
7.5 |
|
| Adjuvant chemotherapy |
No |
155 |
49.5 |
107 |
47.1 |
| Yes |
158 |
50.5 |
120 |
52.9 |
|
| Adjuvant hormonal therapy |
No |
104 |
33.2 |
78 |
34.4 |
| Yes |
209 |
66.8 |
149 |
65.6 |
|
| Adjuvant radiotherapy |
No |
70 |
22.4 |
50 |
22.0 |
| Yes |
243 |
77.6 |
177 |
78.0 |
|
| Mastectomy |
No |
2 |
0.6 |
1 |
0.4 |
| Complete |
217 |
69.3 |
154 |
67.8 |
|
| Partial |
94 |
30.0 |
72 |
31.7 |
|
|
Data are presented for the 313-patient test set cohort, and for the 227-patient subgroup in which expression data were available for each of the eight immunohistochemical biomarkers assessed. Percentages are rounded. | |||||
Crabb et al. Breast Cancer Research 2008 10:R6 doi:10.1186/bcr1847 |
|||||